Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Blue Earth Diagnostics
With
American College of Radiology
IND 2 Results LLC
Syne Qua Non Limited
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).
Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :
Post prostatectomy: Detectable or rising PSA level that is \>0.2 ng/mL with a second confirmatory level of \>0.2 ng/mL
Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir
Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).
Being considered for salvage therapy
Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.
Previous brachytherapy treatment will have occurred at least 2 years in the past
Ability to understand and the willingness to sign a written informed consent.
You may not be if
Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)
Androgen deprivation therapy (ADT) in the past 3 months
History of bilateral orchidectomy
Inability to tolerate 18F-fluciclovine PET/CT
Clareo Health | 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
